New brands mask the long wait for eye care recovery
- PBH is a brand owner that builds revenue through marketing and shelf placement.
- The company recently added Breathe Right and LaCorium to diversify its portfolio away from supply issues.
- Clear Eyes supply remains heavily depressed and now accounts for less than 3 percent of total sales.
- The Pillar5 manufacturing deal closed in December 2025 to help secure future eye care supply.
- The stock depends on successful integration of the new brands while fixing the core eye care supply chain.
Buying growth while waiting on supply
The core PBH thesis is based on owning small but useful health brands that generate steady cash. People buy products like eye drops, yeast infection treatments, hydration powders, earwax removers, and sleep aids because they need them, not because they are trendy.
The main problem remains Clear Eyes. A long supply issue kept PBH from meeting demand, and the brand now represents less than 3 percent of total sales. The recovery timeline has been pushed out, placing more pressure on the rest of the business to perform.
To fill the growth void, PBH acquired the Breathe Right and LaCorium brands. Breathe Right brings about $200 million in annual revenue and creates a new wellness and sleep category. This pivot turns the story from a pure turnaround into a portfolio diversification play.
The bear case asks if PBH can run its new Pillar5 facility well enough to rebuild Clear Eyes shipments, and whether it can integrate the new acquisitions without losing focus. The bull case points to the immediate scale from the new brands masking the near term headwinds.
Small health brands, steady cash
PBH makes money by selling over-the-counter healthcare products to retailers. Over-the-counter means products people can buy without a prescription. The company spends on marketing, packaging, product updates, and retailer relationships to keep its brands on shelves and in online carts.
This model works well because the products are low cost and needs based. A consumer with dry eyes, heartburn, dehydration, or a cold usually wants a trusted fix. PBH does not need to invent a new medicine every year to stay relevant.
The weak spot is operations. If PBH cannot make enough product, retailers cannot sell it. Clear Eyes showed how a supply chain issue can turn a steady brand into a drag on revenue. Owning Pillar5 may reduce that risk, but it also puts PBH in the business of running more manufacturing than before.
Capital allocation is part of the story. The company generates strong free cash flow, which it uses for share repurchases and strategic acquisitions like Breathe Right.
Where the brands fit
Eye & Ear Care
Clear Eyes is the key recovery brand, with TheraTears and Debrox also in the group. Ongoing supply challenges have pushed Clear Eyes to under 3 percent of sales.
Women's Health
Monistat and Summer's Eve are important brands in this group. This category provides steady performance.
Wellness, Sleep and Other
A new category formed by the Breathe Right acquisition, representing a low teens percentage of pro forma revenue and about $200 million annually.
Gastrointestinal and Pediatric
Reliable segments that continue to offset weakness elsewhere in the portfolio.
International
Led by Hydralyte in Australia and recently strengthened by the LaCorium Health acquisition, adding about $40 million in annualized revenue.
Mostly North America
The mix reflects fiscal 2026 annual segment revenue before the new acquisitions. North American OTC Healthcare was 83.9 percent of revenue, with International OTC Healthcare at 16.1 percent. The new wellness and sleep category will alter this pro forma mix.
What could break the thesis
Integration of new brands
High impact · Medium oddsPBH just added significant revenue through Breathe Right and LaCorium. If management struggles to integrate these brands while also trying to fix Pillar5, overall growth could stall.
Pillar5 integration misses
High impact · Medium oddsPBH bought Pillar5 to control more of the Clear Eyes supply chain. That helps only if the facility ramps production, meets quality rules, and ships on time.
Clear Eyes share does not come back
High impact · Medium oddsEven as supply improves, shoppers may have tried rival eye drops during the shortage. Retailers may also have given shelf space to competitors.
E-commerce orders stay noisy
Medium impact · High oddsManagement has called out volatile order patterns from a major e-commerce retailer. Those orders can move quarterly sales even when consumer demand is steadier.
In one breath
What does Prestige Consumer Healthcare do?
PBH owns and sells over-the-counter healthcare brands. Its products include eye drops, women's health products, sleep aids, hydration, and stomach care.
Why does Clear Eyes matter so much for PBH?
Clear Eyes has been a major source of pressure because PBH could not make and ship enough product. The brand has shrunk to less than 3 percent of sales, making its recovery a key focus.
Is PBH mainly a growth stock or a cash flow stock?
Right now it looks more like a cash flow and portfolio integration story. Growth from new acquisitions is masking the ongoing supply issues in the core eye care business.
What is the next thing investors should watch?
Watch whether the new Breathe Right brand meets its revenue targets. The second signal is whether Clear Eyes production at Pillar5 improves in the second half of fiscal 2027.
